Across TCGA pan-cancer cohorts, C9orf152 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C9orf152 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher C9orf152 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C9orf152 expression acts as an unfavorable survival marker.

BLCA, CHOL, and SKCM are the cancer types where C9orf152 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.193	0.684	.008	9	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
SKCM	DFS	Median	III,IV	0.157	0.653	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: C9orf152 tumor-vs-normal RNA expression · all C9orf152 data types